Islet Sciences announces merger with Brighthaven Ventures

1 October 2014

Metabolic biopharma specialist Islet Sciences has announced a merger with Brighthaven Ventures, a privately-held pharma company developing the SGLT2 inhibitor remogliflozin etabonate for type 2 diabetes and non-alcoholic steatohepatitis.

The new company will be named Avogenx and will operate under the leadership of the current Islet management. Avogenx will continue to develop its most advanced clinical asset, BHV’s remogliflozin etabonate, a potential best-in-class SGLT2 inhibitor that has been dosed in more than 800 patients in 21 clinical trials, including two successful Phase IIb studies. Brighthaven expects to initiate a multi-center Phase IIb study in the fourth quarter of 2014 in patients with type 2 diabetes, and an additional phase IIb study for the non-alcoholic steatohepatitis indication in 2015.

Best in class product

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK